Trials / Suspended
SuspendedNCT00536770
A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer
A Randomized Phase 2 Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Subjects With Advanced Pancreatic Adenocarcinoma
- Status
- Suspended
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 132 (estimated)
- Sponsor
- Novacea · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and efficacy of an investigational study drug DN-101 (calcitriol) when given in combination with gemcitabine ± erlotinib in the treatment of pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | placebo + gemcitabine + erlotinib | |
| DRUG | Placebo + gemcitabine | |
| DRUG | calcitriol + gemcitabine | |
| DRUG | calcitriol + gemcitabine + erlotinib |
Timeline
- Start date
- 2007-09-01
- First posted
- 2007-09-28
- Last updated
- 2007-11-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00536770. Inclusion in this directory is not an endorsement.